Today, Pillar Pacific Capital Management LLC Sold shares of DexCom Inc. (DXCM)

Today, Pillar Pacific Capital Management LLC Sold shares of DexCom Inc. (DXCM)
Pillar Pacific Capital Management LLC decreased its stake in shares of DexCom Inc. (NASDAQ:DXCM) by 0.1% during the third quarter, Holdings Channel reports. The institutional investor owned 5,500 shares of the medical device company’s stock after selling 7 shares during the period. Pillar Pacific Capital Management LLC’s holdings in DexCom were worth $482,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in DXCM. Patten & Patten Inc. TN boosted its position in shares of DexCom by 3.6% in the second quarter. Patten & Patten Inc. TN now owns 50,425 shares of the medical device company’s stock worth $4,000,000 after buying an additional 1,775 shares during the period. Shaker Investments LLC OH boosted its position in shares of DexCom by 16.1% in the second quarter. Shaker Investments LLC OH now owns 79,145 shares of the medical device company’s stock worth $6,279,000 after buying an additional 11,000 shares during the period. Eqis Capital Management Inc. boosted its position in shares of DexCom by 1.7% in the second quarter. Eqis Capital Management Inc. now owns 7,246 shares of the medical device company’s stock worth $575,000 after buying an additional 119 shares during the period. Eagle Asset Management Inc. bought a new position in shares of DexCom during the second quarter worth approximately $10,857,000. Finally, Dowling & Yahnke LLC boosted its position in shares of DexCom by 29.8% in the second quarter. Dowling & Yahnke LLC now owns 18,642 shares of the medical device company’s stock worth $1,479,000 after buying an additional 4,279 shares during the period.

Shares of DexCom Inc. (NASDAQ:DXCM) traded up 0.87% on Friday, reaching $72.82. The company had a trading volume of 472,540 shares. The company’s market capitalization is $6.16 billion. The company has a 50 day moving average of $74.71 and a 200-day moving average of $79.84. DexCom Inc. has a 52 week low of $47.92 and a 52 week high of $96.38.

A number of equities analysts have recently commented on the company. B. Riley reiterated a “neutral” rating and issued a $84.00 target price on shares of DexCom in a report on Wednesday, November 2nd. BTIG Research restated a “buy” rating and set a $92.00 price objective on shares of DexCom in a report on Thursday, August 4th. Oppenheimer Holdings Inc. set a $84.00 price objective on DexCom and gave the company a “hold” rating in a report on Wednesday, November 2nd. Wedbush restated an “outperform” rating and set a $112.00 price objective (up previously from $100.00) on shares of DexCom in a report on Wednesday, November 2nd. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $100.00 price objective (up previously from $93.00) on shares of DexCom in a report on Thursday, August 4th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. DexCom has a consensus rating of “Buy” and a consensus price target of $92.07.

In related news, CFO Jess Roper sold 2,470 shares of the stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $93.99, for a total value of $232,155.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 7,000 shares of the stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $91.79, for a total value of $642,530.00. The disclosure for this sale can be found here. 2.80% of the stock is owned by corporate insiders.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

Related posts

Leave a Comment